Aspirin-Fumaric Acid Combination for MS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for multiple sclerosis (MS) using dimethyl fumarate (DMF) and its metabolite, monomethyl fumarate (MMF), are limited by side effects such as cutaneous flush, which can lead to non-compliance due to intolerance.
Innovation Solution
The administration of aspirin in conjunction with fumaric acid or its esters/salts, such as DMF and MMF, enhances the bioavailability of fumaric acid, allowing for a lower effective dose without compromising treatment outcomes, and enables patients to tolerate higher doses with reduced side effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If dimethyl fumarate (DMF) and monomethyl fumarate (MMF) are used to treat multiple sclerosis, then treatment efficacy is improved, but cutaneous flush side effects increase
Solution Approach 1:
Aspirin is introduced as an intermediary substance that modifies the interaction between fumaric acid esters and the patient's body. The aspirin-fumaric acid combination enhances bioavailability and reduces cutaneous flush, acting as a mediator that improves the risk-benefit ratio of the treatment
Solution Approach 2:
The patent changes the dosing parameters by allowing lower doses of fumaric acid (360-480 mg/day) when combined with aspirin, compared to conventional higher doses. This parameter change maintains efficacy while reducing harmful side effects through the synergistic interaction with aspirin
2Reliability
If higher doses of fumaric acid or its esters are administered, then treatment outcome is improved, but patient tolerance decreases due to side effects
Solution Approach 1:
Aspirin serves as a protective intermediary that reduces the toxic effects of higher fumaric acid doses. This allows patients to tolerate higher effective doses without experiencing excessive side effects, improving both treatment outcome and patient comfort
Solution Approach 2:
Aspirin is administered concurrently with fumaric acid to pre-establish protective effects against cutaneous flush and other side effects. This preliminary protective action enables patients to tolerate higher doses of fumaric acid without compromising safety or comfort
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of aspirin and fumaric acid or its esters/salts increases bioavailability, allowing for a lower daily dose of fumaric acid (e.g., 360 mg) to achieve the same efficacy as a conventional 480 mg dose, while also reducing side effects and improving patient tolerance.
Implementation Method 1
The administration of aspirin in conjunction with fumaric acid or its esters/salts, such as DMF and MMF, enhances the bioavailability of fumaric acid
Data Source
AI summary
Provided are compositions and methods for treating multiple sclerosis (MS). One embodiment of the disclosed method entails orally administering to a MS patient a first amount of aspirin and a second amount of fumaric acid or an ester or a salt thereof. In some embodiments, the aspirin is administered at from about 80 mg to about 500 mg per day and the fumaric acid or ester or salt thereof is administered at about 360 mg per day.